IGM Biosciences (IGMS)

Company Profile

Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Company profile

Ticker

IGMS

Exchange

NASDAQ

Website

igmbio.com

CEO

Fred M. Schwarzer

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

Former names

Palingen, Inc.

SEC CIK

0001496323

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

IGM Infectious Diseases, Inc. • IGM Autoimmunity and Inflammation, Inc. ...

IRS number

770349194

IGMS stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$31.33

Low target

$22.00

High target

$45.00

Latest filings (excl ownership)

View all

EFFECT

Notice of effectiveness

IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update

3 Nov 22

Prospectus supplement

8 Aug 22

8-K

IGM Biosciences Announces Second Quarter 2022 Financial Results and Provides Corporate Update

8 Aug 22

Submission of Matters to a Vote of Security Holders

24 Jun 22

8-K

Departure of Directors or Certain Officers

1 Jun 22

8-K

IGM Biosciences Announces First Quarter 2022 Financial Results and Provides Corporate Update

9 May 22

Transcripts

IGMS

Earnings call transcript

2020 Q4

31 Mar 21

IGMS

Earnings call transcript

2019 Q4

26 Mar 20

Latest ownership filings

View all

Financial summary

Financial statements Chart IGMS financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	178.11 mm	178.11 mm	178.11 mm	178.11 mm	178.11 mm	178.11 mm
Cash burn (monthly)	14.62 mm	(no burn)	20.17 mm	18.53 mm	13.47 mm	221.00 k
Cash used (since last report)	31.28 mm	n/a	43.15 mm	39.64 mm	28.82 mm	472.78 k
Cash remaining	146.83 mm	n/a	134.96 mm	138.46 mm	149.29 mm	177.63 mm
Runway (months of cash)	10.0	n/a	6.7	7.5	11.1	803.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2022

IGMS institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	92	99	-7.1%
Opened positions	16	29	-44.8%
Closed positions	23	21	+9.5%
Increased positions	31	33	-6.1%
Reduced positions	26	19	+36.8%

13F shares	Current	Prev Q	Change
Total value	11.17 bn	1.68 bn	+564.2%
Total shares	31.50 mm	32.24 mm	-2.3%
Total puts	14.00 k	327.40 k	-95.7%
Total calls	108.30 k	404.20 k	-73.2%
Total put/call ratio	0.1	0.8	-84.0%

Largest owners	Shares	Value	Change
Haldor Topsoe Holding A/S	12.67 mm	$1.10 bn	0.0%
Redmile	3.33 mm	$60.12 mm	0.0%
Baker Bros. Advisors	3.16 mm	$56.91 mm	0.0%
T. Rowe Price	2.62 mm	$47.29 mm	+16.8%
Artal	2.00 mm	$36.06 mm	0.0%
Artal International S.C.A.	1.33 mm	$93.44 mm	0.0%
Alkeon Capital Management	1.03 mm	$18.64 mm	0.0%
BLK Blackrock	723.71 k	$13.05 mm	+4.2%
Millennium Management	589.40 k	$10.63 mm	+166.3%
Ubs Global Asset Management Americas	536.41 k	$9.67 bn	-4.3%

Largest transactions	Shares	Bought/sold	Change
Cormorant Asset Management	0.00	-402.20 k	EXIT
T. Rowe Price	2.62 mm	+376.83 k	+16.8%
Millennium Management	589.40 k	+368.09 k	+166.3%
Vanguard	510.93 k	-319.14 k	-38.4%
EcoR1 Capital	0.00	-298.60 k	EXIT
GS Goldman Sachs	198.55 k	-229.53 k	-53.6%
Woodline Partners	200.05 k	-203.35 k	-50.4%
Marshall Wace	252.74 k	+194.68 k	+335.3%
Islet Management	0.00	-131.70 k	EXIT
D. E. Shaw & Co.	274.55 k	-111.16 k	-28.8%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

IGMS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
23 Nov 22	George Gauthier	Common Stock	Sell	Dispose S	No	No	21.9914	397	8.73 k	23,978
23 Nov 22	George Gauthier	Common Stock	Sell	Dispose S	No	No	21.3765	861	18.41 k	24,375
23 Nov 22	Lisa Lynn Decker	Common Stock	Sell	Dispose S	No	No	21.9914	397	8.73 k	20,277
23 Nov 22	Lisa Lynn Decker	Common Stock	Sell	Dispose S	No	No	21.3765	861	18.41 k	20,674
23 Nov 22	Keyt Bruce	Common Stock	Sell	Dispose S	No	No	21.9914	277	6.09 k	38,612
23 Nov 22	Keyt Bruce	Common Stock	Sell	Dispose S	No	No	21.3765	600	12.83 k	38,889
23 Nov 22	Schwarzer Fred	Common Stock	Sell	Dispose S	No	No	21.9914	397	8.73 k	32,729
23 Nov 22	Schwarzer Fred	Common Stock	Sell	Dispose S	No	No	21.3765	861	18.41 k	33,126
23 Nov 22	Misbah Tahir	Common Stock	Sell	Dispose S	No	No	21.9914	277	6.09 k	33,174
23 Nov 22	Misbah Tahir	Common Stock	Sell	Dispose S	No	No	21.3765	600	12.83 k	33,451